Navigation Links
Afid Therapeutics Obtains Positive Evaluation of its Triple Mode,Viral Sequestration Agents

LANSING, Mich., March 27, 2007 /PRNewswire/ -- Afid Therapeutics, Inc. announced that it received positive results on the ability of its new triple mode viral sequestration agents to block viral infections of mammalian cells. The audited results were obtained from a specialized, independent third party testing organization. The new viral sequestrating agents are designed to bind and inactivate viruses by 3 critical mechanisms thus blocking infection. They are aimed at viruses responsible for common causes of influenza in addition to SARS, bird flu and other avian influenzas. "Carbohydrate interactions are critical to the infection process in these systems. The technology capitalizes on the companies' rich carbohydrate chemistry technology portfolio and expertise," said Afid Founder and President Rawle Hollingsworth. Dr. Hollingsworth is a world authority on carbohydrate chemistry and holds nearly 50 issued US patents, scores of international patents and well over 100 publications on many aspects of carbohydrate chemistry critical to the success of the effort. The company intends to pursue both therapeutic and non- therapeutic applications. "The chemistry can be done easily enough that applications in public health, environmental, personal care and defense arenas are well within reach," adds Hollingsworth. "There are no real obstacles to scaling up," said Dr. Li Gao, Afid's research director.

Afid Therapeutics, Inc. was the first start-up firm to receive support from the "Rational Siting Push-Pull Accelerator" (RSPPA) grant to Michigan State University (MSU) from the Michigan Technology Tri-Corridor. The company recently received a $1.66M award from the Michigan 21st Century Jobs Creation Fund. It specializes in advanced chemistry based on carbohydrates with a focus on the drug discovery and development areas and provides advanced chemical intermediates to over 50 pharmaceutical clients around the world.< /p>

CONTACT: Dr. Rawle I. Hollingsworth +1-517-336-4663, Fax +1-517-324-1912, rih@afidtherapeutics.com

Web site: http://www.afidtherapeutics.com/

Terms and conditions of use apply
Copyright © 2007 PR Newswire Association LLC. All rights reserved.
A United Business Media Company


'"/>




Related medicine technology :

1. Cell Therapeutics, Inc. Management to Discuss Todays Announcement of Interim Pixantrone Study Results
2. Halozyme Therapeutics Enhanze Technology Large Protein Molecule Therapeutic Clinical Trial Results Presented at the 34th Annual Meeting of the Controlled Release Society
3. CV Therapeutics Identifies Potential Anti-Diabetic Mechanism of Action for Ranexa
4. Fat Kills Cancer: Turning Stem Cells from Fat Tissue into Personalized, Cancer-Targeted Therapeutics
5. A 4-Week Therapy with Transition Therapeutics E1-I.N.T. Leads to Sustained Reductions in Blood Glucose Levels for 6 Months Post-treatment in Type 2 Diabetes Patients
6. Clinical Trial Suggests Bone Marrow Stem Cells Are Useful for Spinal Cord Injury; PrimeCell Therapeutics Provided Pre-Clinical Study
7. Opexa Therapeutics Reports Positive Top-line Data in Phase I/II Extension Trial with Tovaxin for Multiple Sclerosis
8. Orexigen Therapeutics to Present Data on Contrave Impact on Visceral Fat and Insulin Resistance at American Diabetes Association 67th Scientific Sessions in Chicago June 23
9. Allos Therapeutics Reports Results for Phase 3 Enrich Study of Efaproxyn in Women With Brain Metastases Originating From Breast Cancer
10. Trophos Publishes ALS Article in Journal of Pharmacology and Experimental Therapeutics
11. Novelos Therapeutics Announces Encouraging Results in Ongoing Phase 2 Ovarian Cancer Trial at Dana-Farber/Partners Cancer Care
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:10/10/2017)... -- NDS received FDA 510(k) clearance in May 2017 for its highly ... designed for endoscopy environments. An innovative secondary monitor solution, ZeroWire ... support the improvement of patient outcomes, procedural efficiency, and the lowering ... ... ...
(Date:10/4/2017)... 4, 2017  South Korean-based healthcare product Development Company ... "cprCUBE" on Kickstarter. The device will educate the user ... with better efficiency compared to the dated and pricey ... on efficacy of the compression for a more informed ... goal to raise $5,000. ...
(Date:10/2/2017)... 2017  Eli Lilly and Company (NYSE: ... third quarter of 2017 on Tuesday, October 24, 2017. ... day with the investment community and media to further ... call will begin at 9 a.m. Eastern time. Investors, ... webcast of the conference call through a link that ...
Breaking Medicine Technology:
(Date:10/13/2017)... (PRWEB) , ... October 13, 2017 , ... Apple ... care services, staged a mock evacuation of the facility as part of a disaster ... Fire Department, Echo Hose EMS and Shelton City Emergency Manager, as well as the ...
(Date:10/13/2017)... , ... October 13, 2017 , ... Global Healthcare Management’s ... Alexandria Park in Milford, NJ. This free event, sponsored by Global Healthcare Management’s ... The fun run is geared towards children of all ages; it is a ...
(Date:10/13/2017)... ... October 13, 2017 , ... “The Journey: From the ... danger possible to save lost souls in the Philippines. “The Journey: From the Mountains ... a dedicated teacher of the Bible. She has taught all ages and currently teaches ...
(Date:10/12/2017)... ... October 12, 2017 , ... Planet Fitness, one of the largest and ... plans to open a flagship location in Covington, LA at 401 N. U.S. Highway ... store next to Office Depot in the Holiday Square shopping center. Its location allows ...
(Date:10/12/2017)... ... 2017 , ... Asante, a nationally recognized health system in ... existing home health joint venture through an agreement, effective October 1, 2017, to ... home health company with Asante, delivering clinically integrated care, for the past eight ...
Breaking Medicine News(10 mins):